The University of Iowa

Publications

Safety and Tolerability of SRX246, a Vasopressin 1a Antagonist, in Irritable Huntington’s Disease Patients—A Randomized Phase 2 Clinical Trial

Michael J. Brownstein, Neal G. Simon, Jeffrey D. Long, Jon Yankey, Hilda T. Maibach, Merit Cudkowicz, Christopher Coffey, Robin A. Conwit, Codrin Lungu, Karen E. Anderson, Steven M. Hersch, Dixie J. Ecklund, Eve M. Damiano, Debra E. Itzkowitz, Shifang Lu, Marianne K. Chase, Jeremy M. Shefner, Andrew McGarry, Brenda Thornell, Catherine Gladden, Michele Costigan, Padraig O’Suilleabhain, Frederick J. Marshall, Amy M. Chesire, Paul Deritis, Jamie L. Adams, Peter Hedera, Kelly Lowen, H. Diana Rosas, Amie L. Hiller, Joseph Quinn, Kellie Keith, Andrew P. Duker, Christina Gruenwald, Angela Molloy, Cara Jacob, Stewart Factor, Elaine Sperin, Danny Bega, Zsazsa R. Brown, Lauren C. Seeberger, Victor W. Sung, Melanie Benge, Sandra K. Kostyk, Allison M. Daley, Susan Perlman, Valerie Suski, Patricia Conlon, Matthew J. Barrett, Stephanie Lowenhaupt, Mark Quigg, Joel S. Perlmutter, Brenton A. Wright, Elaine Most, Guy J. Schwartz, Jessica Lamb, Rosalind S. Chuang, Carlos Singer, Karen Marder, Joyce A. Moran, John R. Singleton, Meghan Zorn, Paola V. Wall, Richard M. Dubinsky, Carolyn Gray and Carolyn Drazinic
Journal of Clinical Medicine. Nov 2020; 9 (3682) 1-14.
PubMed: 
PMC7696926

Seven-Year Experience From the National Institute of Neurological Disorders and Stroke-Supported Network for Excellence in Neuroscience Clinical Trials. JAMA Neurology

Merit Cudkowicz, MD, MSc; Marianne K. Chase, BA; Christopher S. Coffey, PhD; Dixie J. Ecklund, RN, MSN, MBA; Brenda J. Thornell, BA; Codrin Lungu, MD; Katy Mahoney, BS; Laurie Gutmann, MD; JeremyM. Shefner,MD, PhD; Kevin J. Staley, MD; Michael Bosch, RN; Eric Foster, PhD; Jeffrey D. Long, PhD; Emine O. Bayman, PhD; James Torner, PhD; Jon Yankey, MS; Richard Peters, BS; Trevis Huff, BSE; Robin A. Conwit, MD; and the NeuroNEXT Clinical Study Sites.
JAMA Neurology. March 23, 2020;
PubMed: 
32202612

Clinical and dopamine transporter imaging characteristics of leucine-rich repeat kinase 2 (LRRK2) and glucosylceramidase beta (GBA) Parkinson's Disease participants in the Parkinson's Progression Markers Initiative: A cross sectional study.

Simuni T, Brumm MC, Uribe L, Caspell-Garcia C, Coffey CS, Siderowf A, Alcalay R, Trojanowski JQ, Shaw LM, Seibyl J, Singleton A, Toga AW, Galasko D, Foroud T, Nudelman K, Tosun-Turgut D, Poston K, Weintraub D, Mollenhauer B, Tanner CM, Kieburtz K, Chahine LM, Reimer A, Hutten S, Bressman S, Marek on behalf of the Parkinson's Progression Markers Initiative Investigators.
Movement Disorders. 2020; 35 (5) 833-844.
PubMed: 
PMC7231646

Clinical and dopamine transporter imaging characteristics of non-manifest LRRK2 and GBA mutation carriers in the Parkinson's Progression Markers Initiative (PPMI): A cross sectional study.

Simuni T, Uribe L, Cho RH, Caspell-Garcia C, Coffey CS, Siderowf A, Trojanowski JQ, Shaw LM, Seibyl J, Singleton A, Toga AW, Galasko D, Foroud T, Tosun-Turgut D, Poston K, Poewe W, Weintraub D, Mollenhauer B, Tanner CM, Kieburtz K, Chahine LM, Reimer A, Hutten S, Bressman, Marek K, on behalf of the PPMI Investigators.
Lancet Neurology . 2020; 19 (1) 71-80.
PubMed: 
PMC6956652